Current concepts in the etiology, diagnosis and treatment of narcolepsy

Sleep Medicine

Volumn 2, Issue 1, 2001, Pages 5-17

  Thorpy, M ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

CNS stimulants; Diagnosis; Drug treatment; Epidemiology; Etiology; Modafinil; Narcolepsy; Quality of life

Indexed keywords

4 AMINOBUTYRIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); CARBEX; CLOMIPRAMINE; DESIPRAMINE; DEXAMPHETAMINE; DOPAMINE; FLUOXETINE; HLA ANTIGEN; HLA DQ ANTIGEN; IMIPRAMINE; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MILNACIPRAN; MIRTAZAPINE; MODAFINIL; NEFAZODONE; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; NORADRENALIN; OREXIN; PEMOLINE MAGNESIUM; PROTRIPTYLINE; PSYCHOSTIMULANT AGENT; REBOXETINE; SELEGILINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANOREXIA; AUTOIMMUNITY; CATAPLEXY; CELL LOSS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG MECHANISM; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HLA SYSTEM; HUMAN; INSOMNIA; IRRITABILITY; LATENT PERIOD; LATERAL HYPOTHALAMUS; LIFESTYLE; NARCOLEPSY; NAUSEA; NERVOUSNESS; POLYSOMNOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEFECT; QUALITY OF LIFE; RELATIVE; REM SLEEP; REVIEW; RISK; SOMNOLENCE; TREMOR;

EID: 0035119687     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1389-9457(00)00081-2     Document Type: Review

References (75)

1. Narcolepsy. Signs, symptoms, differential diagnosis, and management
2. Narcolepsy
3. Validation of a cataplexy questionnaire in 983 sleep-disorders patients
4. Narcolepsy
5. Narcolepsy. Current treatment options
6. International classification of sleep disorders, revised: Diagnostic and coding manual
7. The evolution of narcolepsy with age
8. Childhood narcolepsy
9. Narcolepsy in children
10. Narcolepsy in children
11. The influence of clinical symptoms on quality of life in patients with narcolepsy
12. Life effects of narcolepsy in 180 patients from North America Asia and Europe compared to matched controls
13. Comparison of the psychosocial effects of epilepsy and narcolepsy/cataplexy: A controlled study
14. Psychosocial impact of narcolepsy
15. Genetic and familial aspects of narcolepsy
16. Genetic studies in the sleep disorder narcolepsy
17. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients
18. Neuropharmacology and neurochemistry of canine narcolepsy
19. Neurochemical studies of human narcolepsy: Alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem
20. Autoradiographic studies of post-mortem human narcoleptic brain
21. Dopamine-receptor autoradiography of human narcoleptic brain
22. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene
23. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation
24. Hypocretin (orexin) deficiency in human narcolepsy
25. Diagnostic aspects of narcolepsy
26. Narcolepsy and other causes of excessive daytime sleepiness
27. Guidelines for the multiple sleep latency test (MSLT): A standard measure of sleepiness
28. Practice parameters for the indications for polysomnography and related procedures
29. The clinical use of the multiple sleep latency test
30. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy
31. Maintenance of wakefulness test: A polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence
32. Sleep latency on the maintenance of wakefulness test (MWT) for 530 patients with narcolepsy while free of psychoactive drugs
33. Narcolepsy
34. A normative study of the maintenance of wakefulness test (MWT)
35. Maintenance of wakefulness test and multiple sleep latency test. Measurement of different abilities in patients with sleep disorders
36. A new method for measuring daytime sleepiness: The epworth sleepiness scale
37. Daytime sleepiness and sleep habits of Australian workers
38. The clinical diagnosis of the narcoleptic syndrome
39. Comparison of the results of the epworth sleepiness scale and the multiple sleep latency test
40. Psychometric evaluation of the stanford sleepiness scale
41. Narcolepsy and its treatment with stimulants
42. Compliance with stimulant medications in patients with narcolepsy
43. Deprenyl (selegilline): The history of its development and pharmacological action
44. Selegeline hydrochloride treatment in narcolepsy, a double-blind, placebo-controlled study
45. REM changes in narcolepsy with selegiline
46. Selegiline in the treatment of narcolepsy
47. Therapy with 1-deprenyl (selegiline) and relation to abuse liability
48. Modafinil: An antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers
49. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil
50. Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms
51. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: Possible involvement of the serotonergic 5-HT3 receptor
52. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: Prevention by local GABAA receptor blockade
53. Modafinil binds to the dopamine uptake carrier site with low affinity
54. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat
55. Differential effects of a new central adrenergic agonist-modafinil and D-amphetamine on sleep and early morning behaviour in young healthy volunteers
56. Narcolepsy
57. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy
58. Self-monitoring cognitive performance during sleep deprivation: Effects of modafinil, d-amphetamine and placebo
59. Modafinil: A double-blind multicentric study
60. Effects of modafinil on symptomatology of human narcolepsy
61. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy
62. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy
63. Long-term efficacy and safety of modafinil (Provigil) for the treatment of excessive daytime sleepiness associated with narcolepsy
64. Canine cataplex is preferentially controlled by adrenergic mechanisms: Evidence using monoamine selective uptake inhibitors and release enhancers
65. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy
66. Fluoxetine suppresses human cataplexy: A pilot study
67. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: A double-blind study
68. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: Double-blind subjective measures
69. Gammahydroxybutyrate and narcolepsy: A double-blind placebo-controlled study
70. Health-related quality of life effects of modafinil for treatment of narcolepsy
71. Narcolepsy: A key role for hypocretins (orexins)
72. Narcolepsy and the hypocretin receptor 2 gene